Related Experiment Videos
A phase II study of spirogermanium in patients with metastatic malignant melanoma. An NCI Canada Clinical Trials
Abstract:
The National Cancer Institute of Canada Clinical Trials Group conducted a phase II study of spirogermanium given daily for 5 days every 3 weeks to previously untreated patients with malignant melanoma. In 21 evaluable patients one complete response was seen (response rate 5%). Disease progression occurred in the other 20 patients. Toxicity was primarily neurologic and mild or moderate in most patients, though there was one treatment related death. In this schedule spirogermanium has extremely limited activity against malignant melanoma and will not contribute significantly to the systemic therapy of this disease.
Insights
SpiroGe conducted a phase II trial for malignant melanoma, showing minimal efficacy. The drug spirogermanium demonstrated limited activity and is unlikely to be a significant treatment option.
Area of Science:
- Oncology
- Clinical Pharmacology
Background:
- Malignant melanoma is a serious skin cancer with limited treatment options.
- Investigating novel chemotherapeutic agents is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and toxicity of spirogermanium in patients with malignant melanoma.
- To determine the potential role of spirogermanium in systemic therapy for this disease.
Main Methods:
- A phase II clinical trial was conducted by the National Cancer Institute of Canada Clinical Trials Group.
- SpiroGe was administered daily for 5 days every 3 weeks to 21 evaluable patients.
- Response rates and toxicity profiles were assessed.
Main Results:
- One complete response (5% response rate) was observed in 21 evaluable patients.
- Disease progression occurred in the remaining 20 patients.
- Adverse events were primarily mild to moderate neurologic toxicities, with one treatment-related death.
Conclusions:
- SpiroGe exhibits extremely limited activity against malignant melanoma with the tested schedule.
- This agent is unlikely to significantly contribute to the systemic therapy of malignant melanoma.
- Further investigation into spirogermanium for melanoma may not be warranted in its current form.